ClinicalTrials.gg
CompletedNCT03941964Updated Mar 20, 2023Results posted

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

A Phase 3 interventional study of Venetoclax and Azacitidine in Acute Myeloid Leukemia (AML) and Cancer, sponsored by AbbVie. Completed at 16 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-03-20.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.

Enrollment
84th of 211
60 · median 50
Started
2019
with 8 others
Phase 3
26 of 214
7 open now
Registered
98th of 214
by date
Lead sponsor
6 of 214
AbbVie

Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 84th largest by enrollment of the 211 interventional ones that give a count, is one of 9 that started in 2019, is one of 26 in phase 3, and was the 98th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

67 more — sign in →

By country, each count listing its studies:

All 72 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing azacitidine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

A study evaluating the effectiveness and safety of venetoclax, in combination with azacitidine or decitabine, in an outpatient setting for treatment-naïve participants with AML who are ineligible for intensive chemotherapy.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • Cancer

Keywords

  • Acute Myeloid Leukemia (AML)
  • Cancer
  • Treatment-naïve
  • Venetoclax
  • Azacitidine
  • Decitabine
  • Outpatient setting
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has confirmation of acute myeloid leukemia (AML) by World Health Organization (WHO) criteria
  • Participant is deemed by the investigator to be an appropriate candidate for outpatient ramp-up of venetoclax
  • Participant is not eligible to receive treatment with standard cytarabine and anthracycline induction regimens
  • Participant has not received prior treatment for AML (treatment naïve) with the exception of hydroxyurea
  • Participant has no evidence of spontaneous tumor lysis syndrome (TLS) at Screening
  • Participant can have progressed from myelodysplastic syndrome (MDS) or be considered to have secondary AML and could have been treated with growth factors or other agents with the exception of hypomethylating agents
  • Participant has adequate kidney, liver, and hematology laboratory values as detailed in the protocol
  • Has an (ECOG) Performance status of 0 to 3

Exclusion criteria

Exclusion Criteria:

Has a history of the following conditions:

  • Acute promyelocytic leukemia
  • Known active central nervous system involvement with AML
  • Positive for (HIV testing is not required)
  • Positive for or C infection with the exception of those with an undetectable viral load within 3 months
  • Cardiovascular disability status of Class > 2
  • Chronic respiratory disease that requires continuous oxygen or any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study
  • Malabsorption syndrome or other condition that precludes enteral route of administration

Has a history of other within 2 years prior to study entry, with the exception of:

  • Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast
  • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
  • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Venetoclax 400 mg + azacitidine 75 mg

    Participants received venetoclax orally daily for 28-day cycles, for a maximum of 6 cycles, beginning on Cycle 1 Day 1. The venetoclax dosing ramp-up schedule was 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, and 400 mg on Cycle 1 Days 3 -28 and 400 mg daily for each 28-day cycle thereafter. Azacitidine (75 mg/m\^2) was administered subcutaneously or intravenously per investigator's choice and institutional practice for 7 days beginning on Day 1 of each 28-day cycle.

    Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    Venetoclax 400 mg + decitabine 20 mg

    Participants received venetoclax orally daily for 28-day cycles, for a maximum of 6 cycles, beginning on Cycle 1 Day 1. The venetoclax dosing ramp-up schedule was 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, and 400 mg on Cycle 1 Days 3 -28 and 400 mg daily for each 28-day cycle thereafter. Decitabine (20 mg/m\^2) was administered intravenously per investigator's choice and institutional practice for 5 days beginning on Day 1 of each cycle.

    Drug: Venetoclax · Drug: Decitabine

Interventions

  • Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.

    Also known as: ABT-199, VENCLEXTA, VENCLYXTO

  • The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.

    Also known as: Vidaza

  • The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.

    Also known as: Dacogen

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)

    The composite complete remission rate is defined as the percentage of participants with complete remission (CR) or complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML: CR: Absolute neutrophil count (ANC) \> 10\^3/μL (1,000/μL), platelets \> 10\^5/μL (100,000/μL), red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts CRi: Bone marrow with \< 5% blasts, and absolute neutrophils of ≤ 10\^3/μL or platelets ≤ 10\^5/μL

    Time frame: Assessed at Cycle 1 end, at Cycle 2 end if CR/CRi wasn't achieved at Cycle 1 end, or Cycle 4 end if CR/CRi wasn't achieved at Cycle 2 end. Median treatment duration of venetoclax was 16.1 wks (range 3.9-38.1) and 21.1 wks (range 2.7-40.4), respectively.

Secondary outcomes

  1. Percentage of Participants With Complete Remission (CR)

    The complete remission rate is defined as the percentage of participants with complete remission (CR) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML: CR: Absolute neutrophil count (ANC) \> 10\^3/μL (1,000/μL), platelets \> 10\^5/μL (100,000/μL), red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts

    Time frame: Assessed at Cycle 1 end, at Cycle 2 end if CR/CRi wasn't achieved at Cycle 1 end, or Cycle 4 end if CR/CRi wasn't achieved at Cycle 2 end. Median treatment duration of venetoclax was 16.1 wks (range 3.9-38.1) and 21.1 wks (range 2.7-40.4), respectively.

  2. Percentage of Participants With Complete Remission With Incomplete Blood Count Recovery (CRi)

    The complete remission with incomplete blood count recovery rate is defined as the percentage of participants with complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML: CRi: Bone marrow with \< 5% blasts, and absolute neutrophils of ≤ 10\^3/μL or platelets ≤ 10\^5/μL.

    Time frame: Assessed at Cycle 1 end, at Cycle 2 end if CR/CRi wasn't achieved at Cycle 1 end, or Cycle 4 end if CR/CRi wasn't achieved at Cycle 2 end. Median treatment duration of venetoclax was 16.1 wks (range 3.9-38.1) and 21.1 wks (range 2.7-40.4), respectively.

  3. Percentage of Participants With Post-baseline Transfusion Independence

    The transfusion independence rate is defined as the percentage of participants with post-baseline transfusion independence, which is defined as a period of at least 56 days with no transfusion after the first dose of study drug and within 30 days of the last dose of study drug, death, or initiation of post-treatment therapy, whichever is earliest.

    Time frame: From the first dose of study drug to the last dose of study drug +30 days, or death, or initiation of post-treatment therapy, whichever occurred earliest. Median time on follow-up was 183.5 days and 195.0 days, respectively.

07

Results

Posted Mar 20, 2023

Participant flow

Participant flow — Overall Study
MilestoneVenetoclax 400 mg + Azacitidine 75 mgVenetoclax 400 mg + Decitabine 20 mg
Started3030
Completed711
Not completed2319
Withdrew: Adverse event18
Withdrew: Progressive disease73
Withdrew: Lack of efficacy01
Withdrew: Death31
Withdrew: Withdrew consent13
Withdrew: Physician decision92
Withdrew: Other, not specified21

Outcome measures

PrimaryPercentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)

The composite complete remission rate is defined as the percentage of participants with complete remission (CR) or complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML: CR: Absolute neutrophil count (ANC) \> 10\^3/μL (1,000/μL), platelets \> 10\^5/μL (100,000/μL), red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts CRi: Bone marrow with \< 5% blasts, and absolute neutrophils of ≤ 10\^3/μL or platelets ≤ 10\^5/μL

Time frame:
Assessed at Cycle 1 end, at Cycle 2 end if CR/CRi wasn't achieved at Cycle 1 end, or Cycle 4 end if CR/CRi wasn't achieved at Cycle 2 end. Median treatment duration of venetoclax was 16.1 wks (range 3.9-38.1) and 21.1 wks (range 2.7-40.4), respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)
percentage of participantsVenetoclax 400 mg + Azacitidine 75 mgVenetoclax 400 mg + Decitabine 20 mg
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)70.0 (50.6 to 85.3)63.3 (43.9 to 80.1)
SecondaryPercentage of Participants With Complete Remission (CR)

The complete remission rate is defined as the percentage of participants with complete remission (CR) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML: CR: Absolute neutrophil count (ANC) \> 10\^3/μL (1,000/μL), platelets \> 10\^5/μL (100,000/μL), red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts

Time frame:
Assessed at Cycle 1 end, at Cycle 2 end if CR/CRi wasn't achieved at Cycle 1 end, or Cycle 4 end if CR/CRi wasn't achieved at Cycle 2 end. Median treatment duration of venetoclax was 16.1 wks (range 3.9-38.1) and 21.1 wks (range 2.7-40.4), respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission (CR)
percentage of participantsVenetoclax 400 mg + Azacitidine 75 mgVenetoclax 400 mg + Decitabine 20 mg
Percentage of Participants With Complete Remission (CR)13.3 (3.8 to 30.7)26.7 (12.3 to 45.9)
SecondaryPercentage of Participants With Complete Remission With Incomplete Blood Count Recovery (CRi)

The complete remission with incomplete blood count recovery rate is defined as the percentage of participants with complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML: CRi: Bone marrow with \< 5% blasts, and absolute neutrophils of ≤ 10\^3/μL or platelets ≤ 10\^5/μL.

Time frame:
Assessed at Cycle 1 end, at Cycle 2 end if CR/CRi wasn't achieved at Cycle 1 end, or Cycle 4 end if CR/CRi wasn't achieved at Cycle 2 end. Median treatment duration of venetoclax was 16.1 wks (range 3.9-38.1) and 21.1 wks (range 2.7-40.4), respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission With Incomplete Blood Count Recovery (CRi)
percentage of participantsVenetoclax 400 mg + Azacitidine 75 mgVenetoclax 400 mg + Decitabine 20 mg
Percentage of Participants With Complete Remission With Incomplete Blood Count Recovery (CRi)56.7 (37.4 to 74.5)36.7 (19.9 to 56.1)
SecondaryPercentage of Participants With Post-baseline Transfusion Independence

The transfusion independence rate is defined as the percentage of participants with post-baseline transfusion independence, which is defined as a period of at least 56 days with no transfusion after the first dose of study drug and within 30 days of the last dose of study drug, death, or initiation of post-treatment therapy, whichever is earliest.

Time frame:
From the first dose of study drug to the last dose of study drug +30 days, or death, or initiation of post-treatment therapy, whichever occurred earliest. Median time on follow-up was 183.5 days and 195.0 days, respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With Post-baseline Transfusion Independence
percentage of participantsVenetoclax 400 mg + Azacitidine 75 mgVenetoclax 400 mg + Decitabine 20 mg
Red blood cells (RBC)50.0 (31.3 to 68.7)60.0 (40.6 to 77.3)
Platelets73.3 (54.1 to 87.7)73.3 (54.1 to 87.7)
RBC and platelets50.0 (31.3 to 68.7)60.0 (40.6 to 77.3)

Adverse events

Collected over All-cause mortality is reported from enrollment to end of study; median time on follow up was 183.5, 195.0 and 195.0 days, respectively. TEAEs and SAEs were collected from first dose of study drug until 30 days after last dose of study drug; mean time on venetoclax was 18.2, 18.6, and 18.4 weeks, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Venetoclax 400 mg + Azacitidine 75 mg5/30 (16.7%)19/30 (63.3%)29/30 (96.7%)
Venetoclax 400 mg + Decitabine 20 mg8/30 (26.7%)22/30 (73.3%)30/30 (100%)
Venetoclax 400 mg + Azacitidine 75 mg or Decitabine 20 mg13/60 (21.7%)41/60 (68.3%)59/60 (98.3%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventVenetoclax 400 mg + Azacitidine 75 mgVenetoclax 400 mg + Decitabine 20 mgVenetoclax 400 mg + Azacitidine 75 mg or Decitabine 20 mg
FEBRILE NEUTROPENIABlood and lymphatic system disorders8/3010/3018/60
SEPSISInfections and infestations2/308/3010/60
PYREXIAGeneral disorders0/303/303/60
HYPOTENSIONVascular disorders3/300/303/60
PANCYTOPENIABlood and lymphatic system disorders2/300/302/60
CARDIAC FAILURE CONGESTIVECardiac disorders2/301/303/60
DEATHGeneral disorders2/302/304/60
DISEASE PROGRESSIONGeneral disorders2/301/303/60
PNEUMONIAInfections and infestations2/301/303/60
TUMOUR LYSIS SYNDROMEMetabolism and nutrition disorders2/300/302/60
Most frequent other events
Showing 10 of 76
Most frequent other events
EventVenetoclax 400 mg + Azacitidine 75 mgVenetoclax 400 mg + Decitabine 20 mgVenetoclax 400 mg + Azacitidine 75 mg or Decitabine 20 mg
ANAEMIABlood and lymphatic system disorders23/3024/3047/60
NEUTROPHIL COUNT DECREASEDInvestigations19/3015/3034/60
NAUSEAGastrointestinal disorders17/3015/3032/60
PLATELET COUNT DECREASEDInvestigations14/3016/3030/60
WHITE BLOOD CELL COUNT DECREASEDInvestigations15/3016/3031/60
VOMITINGGastrointestinal disorders13/303/3016/60
FATIGUEGeneral disorders13/3012/3025/60
DIARRHOEAGastrointestinal disorders12/3011/3023/60
CONSTIPATIONGastrointestinal disorders11/308/3019/60
THROMBOCYTOPENIABlood and lymphatic system disorders3/3010/3013/60

Baseline characteristics

All participants who received at least one dose of venetoclax and azacitidine or decitabine

Age, Continuous
Age, Continuous(years)Venetoclax 400 mg + Azacitidine 75 mgVenetoclax 400 mg + Decitabine 20 mgTotal
Mean77.0 ± 6.3176.2 ± 6.3576.6 ± 6.29
Sex: Female, Male
Sex: Female, Male(Participants)Venetoclax 400 mg + Azacitidine 75 mgVenetoclax 400 mg + Decitabine 20 mgTotal
Female151631
Male151429
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Venetoclax 400 mg + Azacitidine 75 mgVenetoclax 400 mg + Decitabine 20 mgTotal
White262955
Black or African American415
Asian000
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
08

Study locations

16 sites
  • Arizona Oncology Associates, PC-HOPE /ID# 211509
    Tempe, Arizona 85284-1812, United States
  • Colorado Blood Cancer Institute /ID# 212800
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers /ID# 211508
    Lone Tree, Colorado 80124, United States
  • Fort Wayne Medical Oncology /ID# 223523
    Fort Wayne, Indiana 46804, United States
  • Minnesota Oncology Hematology, PA /ID# 212837
    Minneapolis, Minnesota 55404, United States
  • Oncology Hematology Care, Inc. /ID# 212779
    Cincinnati, Ohio 45236-2725, United States
  • Willamette Valley Cancer Institute and Research Center /ID# 211504
    Eugene, Oregon 97401-6043, United States
  • Charleston Oncology, P.A. /ID# 211471
    Charleston, South Carolina 29414-7710, United States
  • Prisma Health Cancer Inst - Eastside /ID# 211466
    Greenville, South Carolina 29615, United States
  • Tennessee Oncology - Chattanooga / McCallie /ID# 212717
    Chattanooga, Tennessee 37404-3230, United States
  • Tennessee Oncology-Nashville Centennial /ID# 210944
    Nashville, Tennessee 37203-1632, United States
  • Texas Oncology - Austin Midtown /ID# 212780
    Austin, Texas 78705, United States
  • Texas Oncology - Medical City Dallas /ID# 211503
    Dallas, Texas 75230, United States
  • Texas Transplant Institute /ID# 213311
    San Antonio, Texas 78229, United States
  • Texas Oncology - San Antonio Medical Center /ID# 211510
    San Antonio, Texas 78240-5251, United States
  • Texas Oncology - Northeast Texas /ID# 213908
    Tyler, Texas 75702, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Mar 2022, 30 months.

Results were first posted in Mar 2023, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 30 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2019
First posted
May 8, 2019
StartActual
Aug 15, 2019
Primary completionActual
Mar 14, 2022
CompletionActual
Mar 14, 2022
Results first posted
Mar 20, 2023
Last update
Mar 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03941964
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 8, 2019
Start date
Aug 15, 2019
Primary completion
Mar 14, 2022
Completion
Mar 14, 2022
Results posted
Mar 20, 2023
Last update
Mar 20, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · Decitabine

Start the discussion